Koninklijke Philips N.V. reports health technology developments across Diagnosis & Treatment, Connected Care and Personal Health. News from Royal Philips commonly covers order intake and comparable sales trends; product launches and regulatory clearances for imaging, image-guided therapy and AI software; and governance actions from its Annual General Meeting. Recent product themes include CT platforms such as Rembra and Spectral CT Verida, interventional guidance tools such as DeviceGuide and IntraSight Plus, and the Bridge Plus Occlusion Balloon for lead extraction procedures.
The company’s updates also address hospital monitoring, informatics, ultrasound, oral health and personal-care lines. Coverage reflects Philips’ role as a Netherlands-based global health technology company with securities traded on NYSE under PHG and on Euronext Amsterdam under PHIA.
Royal Philips (NYSE: PHG) announced the exchange ratio for its 2020 dividend, set at 1 new share for every 53.9278 existing shares. This ratio was determined based on a volume weighted average price of EUR 45.8086 from early June 2021. Shareholders had the opportunity to choose between cash and shares until June 4, 2021. 37.7% opted for a share dividend, resulting in 6,345,968 new shares issued. The cash and share dividends will be payable from June 9, 2021. Philips anticipates a reduction in issued shares by year-end 2021 due to share repurchase programs.
On June 7, 2021, Philips (NYSE: PHG) presented its vision for digital transformation in healthcare at the HIMSS and Health 2.0 European Congress. The company showcased scalable, interoperable informatics solutions designed to enhance clinical decision-making, improve patient outcomes, and reduce care costs. Philips emphasized the rising importance of telehealth, as nearly two-thirds of healthcare leaders prioritize investments in this area. Key themes included Healthcare Anywhere, Digital Transformation, and Precision Care, highlighting Philips' robust solutions aimed at optimizing healthcare delivery.
On June 7, 2021, Philips (NYSE: PHG) and Elekta announced an extended strategic partnership to enhance cancer care through precision oncology solutions. This collaboration aims to improve patient outcomes by offering integrated systems for clearer diagnosis and treatment pathways. Notable benefits include quicker visualization of tumors, optimized treatment strategies, and reduced therapy costs. The partnership focuses on leveraging each company's strengths to enhance interoperability between their systems, ultimately striving for better cancer care delivery.
Royal Philips (NYSE: PHG) announced positive results from the Tack Optimized Balloon Angioplasty (TOBA) II clinical trial, demonstrating that its Tack Endovascular System provides sustained treatment effects over two years for patients with Peripheral Artery Disease (PAD) and Critical Limb Ischemia (CLI). Key outcomes include 73.6% freedom from clinically driven target lesion revascularization and 94.7% target limb salvage in CLI patients. The data, presented at the 2021 New Cardiovascular Horizons conference, highlights the significant clinical benefits and improved quality of life for patients treated with this innovative device.
Philips (NYSE: PHG) and Akumin Inc. announced a strategic collaboration to deploy Philips’ Radiology Operations Command Center across Akumin’s outpatient imaging network. This partnership aims to enhance access, quality, and productivity within Akumin’s operations, which involve over 130 outpatient imaging centers across seven U.S. states. The command center will standardize imaging procedures and improve clinical personnel productivity, addressing key radiology challenges. Both companies emphasize the potential for improved patient outcomes and operational efficiency through this innovative approach.
Royal Philips (NYSE: PHG) is partnering with Viamed, a major Spanish private hospital group, to enhance diagnostic imaging across its facilities. Viamed, with 11 hospitals and 15 healthcare centers in Spain, will implement advanced Philips technology, including MR and CT scanners and a digital radiology room. This collaboration aims to improve patient care and maintain healthcare excellence as emphasized by Viamed's CEO. Philips expresses pride in this partnership, which promises to offer superior health outcomes and experiences for both patients and healthcare professionals.
Royal Philips and the University of California, San Francisco (UCSF) announced a partnership focused on enhancing healthcare delivery through AI and cloud-based interoperability. The collaboration aims to streamline patient experiences, improve access to care, and relieve provider workloads. By utilizing Philips HealthSuite, UCSF will develop personalized solutions that integrate various healthcare systems, ultimately enhancing patient care across their networks. This initiative addresses interoperability challenges and aspires to advance better healthcare outcomes while reducing costs.
Royal Philips (NYSE: PHG) announced a share repurchase plan of up to 2 million shares, totaling approximately EUR 91 million. This initiative aims to fulfill obligations from long-term incentive and employee stock purchase plans. The buybacks will occur through forward transactions in the second quarter of 2021, adhering to the Market Abuse Regulation and the authorization from shareholders on May 6, 2021. Shares are expected to be delivered in 2023.
Royal Philips (NYSE: PHG) announced the launch of its new Spectral Computed Tomography (CT) 7500, enhancing precision diagnostics across various patient demographics, including cardiac, pediatric, and bariatric populations. This intelligent system provides high-quality spectral images at standard dose levels, significantly reducing time to diagnosis by 34%, along with a 25% decrease in repeat scans and a 30% reduction in follow-ups. The CT 7500 aims to mitigate the estimated $12 billion annual costs associated with misdiagnosis and inefficient imaging practices.
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG) has announced the European launch of innovative health technology solutions during the EuroPCR 2021 event (May 18-20). The portfolio includes the Interventional Applications Platform – IntraSight Mobile, facilitating coronary disease therapy, and the OmniWire Pressure Guide Wire, the world’s first solid-core pressure wire for coronary interventions, now CE marked. Additionally, the Philips Laser System simplifies coronary and peripheral atherectomy procedures, enhancing clinical efficiency and patient care.